

Neurizon Completes Initial Drawdown Under Non-Dilutive R&D Financing Facility

Highlights:

- First drawdown of ~\$8.3m under the non-dilutive R&D financing facility with the Dare Capital Loan Fund
- Recently secured facility provides access to non-dilutive funding, aligned with the Company's capital markets strategy
- Drawdown is secured against the Company's FY2026 R&D Tax Incentive rebate
- Funds will be directed to core spend activities, predominantly Neurizon's continued investment in the Phase 2/3 HEALEY ALS Platform Trial
- Brings forward access to non-dilutive capital, strengthening near-term funding flexibility and reducing reliance on alternative funding sources, including the Obsidian convertible note facility

11 August 2026 – Melbourne Australia: Neurizon Therapeutics Limited (ASX: NUZ, OTCQB: NUZTF) ("Neurizon" or "the Company") is pleased to announce the completion of an initial drawdown of approximately \$8.3 million under the R&D financing facility with the Dare Capital Loan Fund (the "Facility") (refer ASX announcement: 31 July 2026).

The drawdown of approximately \$8.3 million is secured against the Company's FY2026 R&D Tax Incentive rebate. Proceeds will support core development activities, primarily Neurizon's continued investment in the pivotal Phase 2/3 HEALEY ALS Platform Trial, which is now fully recruited, as the Company advances toward the anticipated topline readout in late Q2 CY2027.

The Facility forms part of Neurizon's broader funding strategy to align capital availability with key clinical milestones while minimising shareholder dilution. It enables access to a non-dilutive secured loan of up to \$17.5 million against the Company's R&D Tax Incentive rebate, with annual extension options to cover the Company's FY2027 and FY2028 R&D Tax Incentive claims. As outlined in the 31 July 2026 announcement, interest accrues at 1.25% per month, capitalising monthly, with repayment triggered upon receipt of the R&D Tax Incentive refund from the Australian Taxation Office.

Chief Financial Officer, Mr Dan O'Connell commented: "Completing this drawdown is a tangible and positive step in the execution of our capital management strategy.

Accessing approximately \$8.3 million of non-dilutive capital earned through our investment in the HEALEY ALS Platform trial strengthens our near-term funding position while reducing our reliance on alternative sources of capital. The facility enables us to bring forward the value of our expected R&D Tax Incentive rebate and continue investing in the development of NUZ-001 as we progress toward the anticipated HEALEY topline readout in late Q2 CY2027."

-ENDS-

This announcement has been authorised for release by the Board of Neurizon Therapeutics Limited.

For further information, please contact:

Marketing and Corporate Affairs

Lidija Damjanovic
Neurizon Therapeutics
lidija@neurizon.com
+61 (0) 425 700 504

Investor Relations

Henry Jordan
Six Degrees Investor Relations
henry.jordan@sdir.com.au
+61 (0) 431 271 538

About Neurizon Therapeutics Limited

Neurizon Therapeutics Limited (ASX: NUZ) is a late-clinical stage biotechnology company dedicated to advancing treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the treatment of ALS, which is the most common form of motor neurone disease. Neurizon's strategy is to accelerate access to effective ALS treatments for patients while exploring the potential of NUZ-001 for broader neurodegenerative applications. Through international collaborations and rigorous clinical programs, Neurizon is dedicated to creating new horizons for patients and families impacted by complex neural disorders. NUZ-001 is an investigational product and is not approved for commercial use in any jurisdiction.

Neurizon Investor Hub

We encourage you to utilise our Investor Hub for any enquiries regarding this announcement or other aspects concerning Neurizon. This platform offers an opportunity to submit questions, share comments, and view video summaries of key announcements.

To access Neurizon Investor Hub please scan the QR code or visit
<https://investorhub.neurizon.com>



Neurizon® is a registered trademark of Neurizon Therapeutics Limited

For personal use only